Nat Med:第二剂BNT162b2加强针对60岁以上成人COVID-19住院和死亡的有效性分析

2022-04-30 MedSci原创 MedSci原创

在60岁及以上的以色列成年人中,由于Covid-19导致的住院和死亡人数大幅减少,这是由接种第二次加强疫苗的结果。

SARS-CoV-2的B.1.1.529(奥密克戎)变异株于2021年11月上旬首次在南非被发现,导致2019年冠状病毒病(COVID-19)在全球范围内空前复苏并广泛传播。以色列当局批准了在上一次接种过第一剂加强针四个月或更长时间且年龄在60岁及以上的个体开始接种第四剂COVID-19疫苗(即第二剂加强针)。因此,收集和整理关于第二次加强针在减少因COVID-19引起的住院和死亡率方面的有效性的证据是十分有必要的。

近日,顶级医学期刊Nature Medicine上发表了一篇研究文章,这项回顾性队列研究纳入了Clalit医疗服务的所有成员,他们年龄在60至100岁之间,且在2022年1月3日前有资格接受了第二次疫苗加强针接种。

研究人员比较了接受第二次加强免疫的参与者与只接受了一次加强免疫的参与者因COVID-19导致的住院和死亡率情况。此外,研究人员使用具有时间依赖性协变量的Cox比例风险回归模型来估计第二次加强免疫与COVID-19导致的住院和死亡之间的关联,同时调整人口因素和合并疾病。

该研究共有563465名参与者符合研究纳入资格和标准。其中,328597人(58%)在40天的研究期间接受了第二次加强疫苗接种。270名接种第二次加强疫苗者和550名只接种一次加强疫苗的参与者发生因COVID-19住院(调整后的风险比为0.36;95%置信区间(CI)为0.31至0.43)。92名接种第二次加强疫苗者和232名只接受一次加强疫苗的参与者发生因COVID-19死亡(调整后的风险比为0.22;95%CI为0.17至0.28)。

这项研究表明,在60岁及以上的以色列成年人中,由于Covid-19导致的住院和死亡人数大幅减少,这是由接种第二次加强疫苗的结果。

原始出处:

Ronen Arbel,et al.Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.Nature Medicine.2022.https://www.nature.com/articles/s41591-022-01832-0_reference.pdf

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1885757, encodeId=9eb71885e57dc, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jan 05 17:36:24 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215978, encodeId=a93212159e823, content=<a href='/topic/show?id=85d5104410a1' target=_blank style='color:#2F92EE;'>#加强针#</a><a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104410, encryptionId=85d5104410a1, topicName=加强针), TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 10:00:40 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215805, encodeId=e8f0121580508, content=谢谢,太棒了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65aa5643711, createdName=小白努力长高高, createdTime=Sat Apr 30 14:23:16 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611562, encodeId=8d3b161156288, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 30 03:36:24 CST 2022, time=2022-04-30, status=1, ipAttribution=)]
    2023-01-05 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1885757, encodeId=9eb71885e57dc, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jan 05 17:36:24 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215978, encodeId=a93212159e823, content=<a href='/topic/show?id=85d5104410a1' target=_blank style='color:#2F92EE;'>#加强针#</a><a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104410, encryptionId=85d5104410a1, topicName=加强针), TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 10:00:40 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215805, encodeId=e8f0121580508, content=谢谢,太棒了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65aa5643711, createdName=小白努力长高高, createdTime=Sat Apr 30 14:23:16 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611562, encodeId=8d3b161156288, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 30 03:36:24 CST 2022, time=2022-04-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1885757, encodeId=9eb71885e57dc, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jan 05 17:36:24 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215978, encodeId=a93212159e823, content=<a href='/topic/show?id=85d5104410a1' target=_blank style='color:#2F92EE;'>#加强针#</a><a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104410, encryptionId=85d5104410a1, topicName=加强针), TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 10:00:40 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215805, encodeId=e8f0121580508, content=谢谢,太棒了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65aa5643711, createdName=小白努力长高高, createdTime=Sat Apr 30 14:23:16 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611562, encodeId=8d3b161156288, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 30 03:36:24 CST 2022, time=2022-04-30, status=1, ipAttribution=)]
    2022-04-30 小白努力长高高

    谢谢,太棒了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1885757, encodeId=9eb71885e57dc, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jan 05 17:36:24 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215978, encodeId=a93212159e823, content=<a href='/topic/show?id=85d5104410a1' target=_blank style='color:#2F92EE;'>#加强针#</a><a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104410, encryptionId=85d5104410a1, topicName=加强针), TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 10:00:40 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215805, encodeId=e8f0121580508, content=谢谢,太棒了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65aa5643711, createdName=小白努力长高高, createdTime=Sat Apr 30 14:23:16 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611562, encodeId=8d3b161156288, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 30 03:36:24 CST 2022, time=2022-04-30, status=1, ipAttribution=)]

相关资讯

Crit Care:血浆半乳糖凝集素3升高与ICU患者主要肾脏不良事件和死亡有关

血浆Gal-3水平与肾功能密切相关,在ICU入院后发生MAKE和死亡风险增加。

Eur Heart J:乳腺癌患者房颤的发生率、危险因素和死亡情况

女性确诊乳腺癌后AF发生率明显更高。诊断时较高的乳腺癌分期与较高的AF风险显著相关。在新的乳腺癌诊断中,新发AF会增加1年心血管死亡率,但不会增加与乳腺癌相关的死亡率。

Clinical Nutrition:不同维生素暴露对于死亡风险的影响

一项发表于国际权威医学杂志的大型研究表明,服用维生素E死亡率增加4%,服用β胡萝卜素死亡率增加7%,服用维生素A死亡率增加16%。

JAHA:功能性二尖瓣关闭不全的严重程度可预测心衰患者再住院和死亡的长期风险

超过一半因急性失代偿性心力衰竭和左心室收缩功能障碍住院的患者至少存在中度功能性二尖瓣关闭不全,这与患者再入院率和死亡率增加相关。

2021 ACR年会:系统性红斑狼疮是老年早期乳腺癌患者死亡的危险因素

比较患有SLE和BC的女性与单独患有BC的女性或没有癌症的SLE女性的生存率。

JAHA:生长分化因子-15可预测伴有心血管危险因素门诊患者的死亡和卒中事件

在伴有心血管危险因素的日本门诊患者中,与NT-proBNP和高敏肌钙蛋白T相比,生长分化因子-15显著改善了全因死亡的风险分层。